ADC Therapeutics SA (ADCT) AI Stock Analysis

ADC Therapeutics SA is a biotechnology company developing antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors. Its key product, ZYNLONTA, is evaluated in Phase II trials for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, Phase III trials with rituximab for second-line transplant-ineligible DLBCL, and Phase I trials for non-Hodgkin lymphoma. The pipeline includes camidanlumab tesirine in Phase II trials for Hodgkin lymphoma, ADCT-602 in Phase Ia for acute lymphoblastic leukemia, and earlier candidates ADCT-601, ADCT-701, and ADCT-901. The company partners with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma, Overland Pharmaceuticals, and MedImmune.

Annual revenue reached $81.4M in FY2025, up 14.9% from $70.8M in FY2024, following a 66.9% decrease in FY2023 from a peak of $209.9M in FY2022. Gross margin remained high at 90.6% in FY2025, compared to 91.6% in FY2024 and 98.4% in FY2022. However, heavy development costs led to an operating margin of -133.2% and a net loss of -$142.6M in FY2025. R&D expenses were $104.0M in FY2025. Over the trailing twelve months ended June 30, 2026, revenue stood at $79.6M with an operating margin of -118.1% and diluted EPS of -$0.60. For the quarter ended June 30, 2026, revenue increased 2.2% year-over-year.

As of June 30, 2026, ADC Therapeutics held $219.1M in cash and short-term investments against $417.1M in total debt, resulting in net debt of $198.0M. Shareholders' equity was -$228.2M on total assets of $279.4M, with a current ratio of 3.03. The company burned -$141.2M in operating cash flow and recorded free cash flow of -$141.4M in FY2025. Capital expenditures totaled $264,000 in FY2025. Financing activities have expanded the share count, which increased 102.9% over five years.

ADCT trades at a price-to-sales ratio of 2.2x and an EV-to-revenue multiple of 0.8x based on an enterprise value of $65.7M and a market capitalization of $178.7M. This represents a discount to the median of its US-listed Healthcare peers, which carries a price-to-sales multiple of 4.1x. Over the past year, ADCT shares declined 66.1%, while the S&P 500 (SPY) gained 16.8%. Over a five-year period, the stock fell 94.5% compared to an 83.0% gain for the benchmark.

Wall Street coverage consists of 3 Strong Buy ratings, 0 Buy ratings, and 2 Hold ratings. The mean price target is $3.33, implying an upside of 138.1% above the last closing price of $1.40. For the current fiscal year ending December 31, 2026, analysts expect revenue of $80.6M and EPS of -$0.75. For FY2027, 4 analysts estimate revenue of $100.9M and EPS of -$0.68. The company has beat EPS estimates in 3 of the last 4 quarters, and its next earnings date is November 9, 2026.

This page is an AI-written research summary of ADC Therapeutics SA (ADCT). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ADCT income statement, ADCT balance sheet, ADCT key metrics, ADCT analyst forecast, ADCT chart. See the ADCT stock overview for the latest quote and news.